Day: January 4, 2024

Signing Day Sports Recruitment AppSigning Day Sports Recruitment App Highly scalable business model, well suited for rapid adaptation across various sports Direct digital marketing expected to drive growth and engagement Collaboration with U.S. Army Bowl showcases the app’s athlete recruitment capabilitiesSigning Day Sports Recruitment AppSCOTTSDALE, Ariz, Jan. 04, 2024 (GLOBE NEWSWIRE) — Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today provided the following letter to stockholders from the Company’s Chairman and CEO, Daniel Nelson: Dear Stockholders, We are pleased to share with you a recap of the significant milestones and exciting developments that...

SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that management will participate in the 13th Annual LifeSci Partners Corporate Access Event, taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week. “We look forward to participating in the LifeSci Corporate Access Event and to hosting in-person meetings with investors, strategic partners, analysts and other stakeholders”, said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “2024 has the potential to be a substantial growth year as we continue to make significant progress on the clinical development of KVA12123, our novel VISTA immunotherapy.” During...

FORT LAUDERDALE, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Golden Grail Beverages (OTC: GOGY), a beverage company dedicated to pioneering and nurturing sustainable brands, celebrates a year of exceptional achievements in 2023, laying a solid foundation for shareholder value in 2024. The company’s strategic rebranding, new product launches, and key partnerships have significantly contributed to its growth and success. Golden Grail Beverages: A Future Filled with Potential in 2024 Golden Grail Beverages enters 2024 with unwavering momentum and a vision for continued growth. The company remains committed to innovating within emerging beverage categories, prioritizing sustainability, and delivering quality and value to consumers. This dedication to transformation, partnership, and responsible growth promises an exciting future...

SARASOTA. Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) announced that its financial results for the fourth quarter of 2023, ended December 31, 2023, will be released before the market opens on Wednesday, January 31, 2024. A conference call to discuss these results has been scheduled for 8:00 AM ET on Wednesday, January 31, 2024. The call can be accessed via webcast or by dialing +1 844-750-4898 (US/Canada) or +1 412-317-5294, using confirmation number 10185260. Webcast information and conference call materials will be made available in the Investors section of Roper’s website prior to the start of the call. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, long-term track record of compounding cash flow and shareholder...

WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company’s Board of Directors, to explore strategic alternatives to maximize shareholder value. Comera will continue to focus on licensing the Company’s proprietary SQore™ technology platform to strategic...

Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating across four distinct market sectors, announced today a significant investment by its Chairman of the Board, Heng Fai Ambrose Chan. In a strategic move to bolster shareholder confidence and underscore his commitment to the company’s growth. Chairman Chan acquired an additional 672,173 shares of DS, Inc. in an open market transaction on December 28, 2023.  Frank Heuszel, CEO of DSS, Inc., expressed his enthusiasm for Mr. Chan’s increased stake, viewing it as a strong vote of confidence in the company’s strategic direction and future potential. Heuszel said, “Chairman Chan’s decision to augment...

Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic Disease BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (“TransCode” or the “Company”) (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced publication of an open letter to shareholders outlining the Company’s progress in 2023 and objectives in 2024. The text of the letter is below. Dear Shareholders, As we begin the new year, we reflect on the challenges faced by the biotech sector over the past two years. Despite those challenges, we have the pleasure to report on TransCode’s progress and resilience and solicit your continued support. Our...

IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) — Mobix Labs, Inc. (Nasdaq: MOBX), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications, and defense industries, today announced it has been awarded a 15-month contract to supply electromagnetic interference (EMI) Filtered Connectors as part of the U.S. Army’s M-1 Abrams Tank program. Under the terms of the agreement, Mobix Labs will supply filtered connectors to an undisclosed Honeywell subcontractor until June 2025. Financial details were not disclosed. “This is a key design win and validation of our successful acquisition of EMI Solutions as we continue to gain further access into the large and important military vertical,” said Fabian Battaglia, CEO of Mobix Labs. “We are honored to be a...

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction. “Since initiating our research collaboration with Bayer in 2020, we have worked diligently to apply the power of the Recursion OS to identify and advance potential candidates in challenging areas of disease...